The relationship of in vivo central CB1 receptor occupancy to changes in cortical monoamine release and feeding elicited by CB1 receptor antagonists in rats

Psychopharmacology

Volumn 184, Issue 1, 2006, Pages 26-35

  Need, Anne B ^a   Davis, Richard J ^a   Alexander Chacko, Jesline T ^a   Eastwood, Brian ^a   Chernet, Eyassu ^a   Phebus, Lee A ^a   Sindelar, Dana K ^a   Nomikos, George G ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

3H SR141716A; Cannabinoid; Dopamine; Feeding; In vivo binding; Microdialysis; Norepinephrine; Receptor occupancy; SLV319; SR141716A

Indexed keywords

4 CHLORO N [[3 (4 CHLOROPHENYL) 4 PHENYL 2 PYRAZOLIN 1 YL](METHYLAMINO) METHYLENE]BENZENESULFONAMIDE; 4 CHLORO N [[3 (4 CHLOROPHENYL) 4 PHENYL 2 PYRAZOLIN 1 YL](METHYLAMINO)METHYLENE]BENZENESULFONAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; DOPAMINE; NORADRENALIN; RECEPTOR SUBUNIT; RIMONABANT; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG LABELING; DRUG POTENCY; DRUG RECEPTOR BINDING; FEEDING BEHAVIOR; FRONTAL CORTEX; IN VIVO STUDY; MALE; MICRODIALYSIS; MONOAMINE RELEASE; NEUROBIOLOGY; NEUROPHARMACOLOGY; NONHUMAN; NORADRENALIN RELEASE; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; RECEPTOR INTRINSIC ACTIVITY; RECEPTOR OCCUPANCY;

ANIMALS; DOPAMINE; FEEDING BEHAVIOR; FRONTAL LOBE; MALE; MICRODIALYSIS; NOREPINEPHRINE; PIPERIDINES; PREFRONTAL CORTEX; PYRAZOLES; RADIOLIGAND ASSAY; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; SULFONAMIDES;

EID: 29344449084     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-005-0234-x     Document Type: Article

References (44)

1. Abel E (1971) Effects of marihuana on the solution of anagrams, memory, and appetite. Nature 231:260-261
2. Arnone M, Maruani J, Chaperon F, Thiebot M, Poncelet MH, Soubrie P, Le Fur G (1997) Selective inhibition of sucrose and ethanol intake by SR141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 132:104-106
3. Breivogel CS, Griffin G, Di Marzo V, Martin BR (2001) Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 60:155-163
4. Cani P, Montoya M, Neyrinck A, Delzenne N, Lambert D (2004) Potential modulation of plasma ghrelin and glucagon-like peptide-1 by anorexigenic cannabinoid compounds, SR14171 6A (rimonabant) and oleoylethanolamide. Br J Nutr 92:757-761
5. Cohen C, Perrault G, Voltz C, Steinberg R, Soubrie P (2002) SR141716, a central cannabinoid (CB1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol 13:451-463
6. Cosenza M, Gifford A, Gatley S, Pyatt B, Liu Q, Makriyannis A, Volkow N (2000) Locomotor activity and occupancy of brain cannabinoid CB1 receptors by the antagonist/inverse agonist AM281. Synapse 38:477-482
7. De Fronseca F, Del Arco I, Martin-Calderon J, Gorriti M, Navarro M (1998) Role of the endogenous cannabinoid system in the regulation of motor activity. Neurobiol Dis 5:483-501
8. Deroche-Gamonet V, Le Moal M, Piazza P, Soubrie P (2001) SR141716, a CB1 receptor antagonist, decreases the sensitivity to the reinforcing effects of electrical brain stimulation in rats. Psychopharmacology (Berl) 157:254-259
9. Devane W, Dysarc F, Johnson M, Mevin L, Howlett A (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34:605-613
10. Devane W, Hanus L, Breuer A, Pertwee R, Stevenson L, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-1949
11. Di Marzo V, Goparaju S, Wang L, Liu J, Batkai S, Jarai Z, Fezza F, Miura G, Palmiter R, Sugiura T, Kunos G (2001) Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410:822-825
12. Durcan M, Denner G, White J, Johnston J, Gonzales D, Niaura R, Rigotti N, Sachs D (2002) The effect of bupropion sustained-release on cigarette craving after smoking cessation. Clin Ther 24:540-551
13. Gallant A (1987) Nonlinear statistical models. Wiley, New York
14. Gaoni Y, Mechoulam R (1964) Isolation, structure and partial synthesis of an active component of hashish. J Am Chem Soc 86:1646-1647
15. Goeders N, Kuhar M (1985) Benzodiazepine receptor binding in vivo with [3H]-Ro 15-1788. Life Sci 37:345-355
16. Gomez R, Navarro M, Ferrer B, Trigo J, Bilbao A, Del Arco I, Cippitelli A, Nava F, Piomelli D, Rodriguez de Fonseca F (2002) A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 22:9612-9617
17. Grundy R (2002) The therapeutic potential of the cannabinoids in neuroprotection. Expert Opin Investig Drugs 11:1365-1374
18. Haller J, Varga B, Ledent C, Freund T (2004) CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents. Behav Pharmacol 15:299-304
19. Lange J, Coolen H, van Stuivenberg H, Dijksman J, Herremans A, Ronken E, Keizer H, Hiskias G, Tipker K, McCreary A, Veerman W, Wals H, Stork B, Verveer P, den Hartog A, de Jong N, Adolfs T, Hoogendoom J, Kruse C (2004) Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB1 cannabinoid receptor antagonists. J Med Chem 47:627-643
20. Li S, Perry K, Wong D (2002) Influence of fluoxetine on the ability of bupropion to modulate extracellular dopamine and norepinephrine concentrations in three mesocorticolimbic areas of rats. Neuropharmacology 42:181-190
21. Lichtman A (2000) SR141716A enhances spatial memory as assessed in a radial-arm maze task in rats. Eur J Pharmacol 404:175-179
22. Matsuda L, Lolait S, Brownstein M, Young A, Bonner T (1990) Structure of cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561-564
23. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski N et al (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to camiabinoid receptors. Biochem Pharmacol 50:83-90
24. Mechoulam R, Fride E, Hanus L, Sheskin T, Bisogno T, Di Marzo V, Bayewitch M, Vogel Z (1997) Anandamide may mediate sleep induction. Nature 389:25-26
25. Monory K, Tzavara ET, Lexime J, Ledent C, Parmentier M, Borsodi A, Hanoune J (2002) Novel, not adenylyl cyclase-coupled cannabinoid binding site in cerebellum of mice. Biochem Biophys Res Commun 292:231-235
26. Munro S, Thomas K, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61-65
27. Navarro M, Carrera M, Fratta W, Valverde O, Cossu G, Fattore L, Chowen J, Gomez R, Del Arco I, Villanua M, Maldonado R, Koub G, Rodriguez de Foncesca F (2001) Functional interaction between opioid and cannabinoid receptors in drug self-administration. J Neurosci 21:5344-5350
28. Nunez E, Benito C, Pazos M, Barbachano A, Fajardo O, Gonzalez S, Tolon R, Romero J (2004) Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: an immunohistochemical study. Synapse 53:208-213
29. Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates. Academic, San Diego
30. Perry K, Fuller R (1997) Fluoxetine increases norepinephrine release in rat hypothalamus as measured by tissue levels of MHPG-SO4 and microdialysis in conscious rats. J Neural Transm 104:953-966
31. Plasse T, Gorter R, Krasnow S, Lane M, Shepard K, Wadleigh R (1991) Recent clinical experience with dronabinol. Pharmacol Biochem Behav 40:695-700
32. Poncelet M, Maruani J, Calassi R, Soubrie P (2003) Overeating, alcohol and sucrose consumption decrease in CB1 receptor deleted mice. Neurosci Lett 343:216-218
33. Ravinet Trillou C, Delgorge C, Menet C, Arnone M, Soubrie P (2004) CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes 28:640-648
34. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B et al (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240-244
35. Robinson L, Riedel G (2004) Cannabinoid function in spatial learning: an update. Curr Neuropharmacol 2:125-143
36. Santucci V, Storme J, Soubrie P, Le Fur G (1996) Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR 141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis. Life Sci 58:PL103-110
37. Simiand J, Keane M, Keane PE, Soubrie P (1998) SR141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav Pharmacol 9:179-181
38. Smith R, Fathi Z (2005) Recent advances in the research and development of CB(1) antagonists. IDrugs 8:53-66
39. Tataranni P, Gautier JF, Chen K, Uecker A, Bandy D, Salbe A, Pratley R, Lawson M, Reiman E, Ravussin E (1999) Neuro-anatomical correlates of hunger and satiation in humans using positron emission tomography. Proc Natl Acad Sci U S A 96:4569-4574
40. Tsou K, Brown S, Sanudo-Pena M, Mackie K, Walker J (1998) Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83:393-411
41. Tzavara E, Davis R, Perry K, Li X, Salhoff C, Bymaster F, Witkin J, Nomikos GG (2003) The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br J Pharmacol 138:544-553
42. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S (2005) Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365:1389-1397
43. Verty A, McGregor I, Mallet P (2004) Consumption of high carbohydrate, high fat, and normal chow is equally suppressed by a cannabinoid receptor antagonist in non-deprived rats. Neurosci Lett 354:217-220
44. Walker M, Huang S (2002) Cannabinoid analgesia. Pharmacol Ther 95:127-135